Abstract
AbstractTargeted protein degradation (TPD) has emerged as a powerful strategy to selectively eliminate cellular proteins using small-molecule degraders, offering therapeutic promise for targeting proteins that are otherwise undruggable. However, a remaining challenge is to unambiguously identify primary TPD targets that are distinct from secondary downstream effects in the proteome. Here we introduce an approach that combines stable isotope labeling and click-chemistry for selective quantification of protein degradation by mass spectrometry, excluding confounding effects of altered transcription and translation induced by target depletion. We show that the approach efficiently operates at the time scale of TPD (hours) and we demonstrate its utility by analyzing the Cyclin K degraders dCeMM2 and dCeMM4, which induce widespread transcriptional downregulation, and the GSPT1 degrader CC-885, an inhibitor of protein translation. Additionally, we apply it to characterize compound 1, a previously uncharacterized degrader, and identify the zinc-finger protein FIZ1 as a degraded target.
Publisher
Cold Spring Harbor Laboratory
Reference46 articles.
1. pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase
2. Lysosome-targeting chimaeras for degradation of extracellular proteins
3. PROTAC targeted protein degraders: the past is prologue
4. An integrated workflow for quantitative analysis of the newly synthesized proteome
5. Bradner James , Roberts Justin , Nabet Behnam , Winter Georg , Phillips Andrew J , Heffernan Timothy P , & Buckley Dennis . (2017). Targeted Protein Degradation to Attenuate Adoptive T-Cell Therapy Associated Adverse Inflammatory Responses (Patent Publication Number: WO-2017024318-A1). World Intellectual Property Organization. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017024318
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献